Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and<i>BRCA1</i>-associated breast carcinomas

Journal of Clinical Pathology - Tập 60 Số 9 - Trang 1006-1012 - 2007
Socorro María Rodríguez‐Pinilla1, David Sarrió1, Emiliano Honrado2, Gema Moreno‐Bueno1, David Hardisson3, Francisco Calero Calero4, Javier Benı́tez2, José Palacios5
1Laboratory of Breast and Gynaecological Cancer, Molecular Pathology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
2Department of Human Genetics, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
3Pathology Department, Hospital Universitario La Paz, Madrid, Spain
4Department of Gynaecology and Obstetrics, Hospital Universitario La Paz, Madrid, Spain
5Hospital Virgen del Rocío, Avda Manuel Siurot, s/n 43013 Sevilla, Spain

Tóm tắt

Aims:To determine whether basal-like phenotype and vimentin and/or laminin are related in both sporadic/familial (BRCA1orBRCA2mutated) tumours.Methods:230 non-familial and 28 hereditary node-negative invasive breast carcinomas were immunohistochemically analysed for oestrogen receptors (ER), progesterone receptors (PR), cytokeratin 5/6 (CK5/6), epidermal growth factor receptors (EGFR), Ki67, p53, vimentin and laminin, using tissue microarrays. Tumours were considered to have basal-like phenotype if they were ER negative and HER2 negative, but positive for CK5/6 and/or EGFR.Results:In sporadic tumours, vimentin expression was found in 77.8% cases with basal-like phenotype and 15.5% of non-basal cases (p<0.001). In familial cases, vimentin was expressed in 83.3% basal-like cancers and 16.7% of non-basal tumours (p<0.001). Vimentin expression was more frequent inBRCA1thanBRCA2mutation carriers. Vimentin expressing tumours were associated with poor prognosis (p = 0.012) among patients not receiving adjuvant chemotherapy and showed a trend for local recurrence or visceral but not bone metastasis (p = 0.021). Laminin expression was also related to basal-like phenotype in both sporadic/familial cases (p<0.001 and p = 0.007, respectively), but neither with prognosis nor recurrence pattern in sporadic cancers.Conclusions:Vimentin and laminin expression is associated with basal-like phenotype in breast cancer. Expression of vimentin and laminin is characteristic ofBRCA1associated tumours. Since vimentin and laminin staining is widely used by pathologists for diagnostic purposes, thus demonstrating the robustness of their specific antibodies, the immunohistochemical evaluation of these two molecules could be used in identification of basal-like breast tumours in both sporadic/familial cases.

Từ khóa


Tài liệu tham khảo

10.1002/(SICI)1096-9896(199608)179:4<386::AID-PATH631>3.0.CO;2-V

10.1186/bcr1041

10.1038/35021093

10.1002/path.1559

10.1093/jnci/djj267

2003, Proc Natl Acad Sci USA, 100, 8414

10.1038/415530a

2003, Am J Pathol, 163, 1991

10.1073/pnas.201162998

10.1158/1078-0432.CCR-04-0429

10.1158/1078-0432.CCR-03-0731

10.1054/bjoc.2001.1869

10.1016/S0046-8177(99)90028-X

10.1097/00000478-200002000-00005

10.1002/path.1845

10.1038/nature03799

10.1158/1078-0432.CCR-04-2421

10.1111/j.1365-2559.2006.02453.x

10.1111/j.1365-2559.2006.02467.x

10.1158/0008-5472.CAN-03-2970

10.1007/s10549-004-1536-0

10.1093/jnci/djg050

10.1093/jnci/djh115

10.1093/jnci/djh115

10.1038/modpathol.3800456

10.1158/1078-0432.CCR-04-2064

10.1158/1078-0432.CCR-04-2424

10.1158/1078-0432.CCR-04-0220

10.1158/1078-0432.CCR-05-2281

1997, Am J Pathol, 150, 483

10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V

10.1002/ijc.2910420202

10.1002/(SICI)1096-9896(199608)179:4<386::AID-PATH631>3.0.CO;2-V

10.1002/path.1711580205

1990, Am J Pathol, 136, 219

1999, Clin Cancer Res, 5, 2698

1990, Am J Pathol, 137, 1299

1995, Cytopathology, 6, 14, 10.1111/j.1365-2303.1995.tb00003.x

2005, Oncol Rep, 14, 337

2005, Cancer Sci, 96, 48, 10.1111/j.1349-7006.2005.00009.x

10.1002/path.1797

10.1002/path.1797

10.1038/modpathol.3800528

10.1002/path.1396

10.1177/002215540104900605

10.1186/bcr1270

2002, J Cell Sci, 115, 39, 10.1242/jcs.115.1.39

10.1186/bcr1286

10.1038/modpathol.3800453

2003, Clin Cancer Res, 1, 3606

10.1007/s10549-006-9184-1

10.1002/jcp.1041500314

10.1007/BF00054016

2001, Cancer Res, 61, 5168

10.1158/1078-0432.CCR-05-0632

10.1007/BF01606456

10.1016/0959-8049(94)00288-G

1994, Anal Quant Cytol Histol, 16, 365

10.1002/(SICI)1097-0215(19960729)67:3<353::AID-IJC8>3.0.CO;2-Q

10.1023/A:1012269804578

2002, Arch Pathol Lab Med, 126, 325, 10.5858/2002-126-0325-MSOERN

10.1080/00313020220131273

2003, Indian J Pathol Microbiol, 46, 579

1993, In Vivo, 7, 601

10.1038/sj.bjc.6602153

10.1097/00000478-200306000-00016

10.1158/1078-0432.CCR-03-0663

1993, Anticancer Res, 13, 851

10.1177/41.4.8450194

10.1007/BF00668209

1998, Clin Cancer Res, 4, 407

2001, Anticancer Res, 21, 1395

2003, Appl Immunohistochem Mol Morphol, 11, 311

2005, Int J Oncol, 27, 1005

Thông tin
Thông tin xuất bản

Journal of Clinical Pathology

Tập 60 Số 9

1006-1012

Thông tin tác giả